Press Release Archive
Press Releases
June 2020
06.29.2020 Responsibility Pfizer Statement on Facebook Advertising Boycott 06.25.2020 Finance Pfizer Declares Third-Quarter 2020 Dividend 06.24.2020 Responsibility Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa 06.23.2020 Research NEW DATA ON THE BURDEN OF EMERGING S. PNEUMONIAE SEROTYPES PUBLISHED IN ISPPD 2020 ONLINE DIGITAL LIBRARY 06.22.2020 Medicines European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma 06.22.2020 Research Vaccines Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines 06.22.2020 Research European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma 06.18.2020 Research Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy 06.18.2020 Finance Investments Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn 06.16.2020 Medicines Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease 06.16.2020 Finance Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts 06.12.2020 Finance Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.